Bone Abstracts

Biomarkers are required to detect early OA for intervention and to monitor disease progression. A collagen type II neoepitope C2C was developed for these purposes. The aims of the study to test: i) the biomarker’s ability to differentiate osteo-arthritis (OA) patients with and without structural changes and ii) possible contribution of progression of the OA.Material and methods: We investigated 159 knee OA patients aged 36–62 (mean 50) years. F...